STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, the dual inhibitory function of STAT3/5 inhibitors is of high clinical relevance since Imatinib-resistant CML cells upregulate and activate STAT3, which represents a major signaling node conferring TKI resistance [8].